Alternative Vaccination Schedules (0, 1, and 6 Months versus 0, 1, and 12 Months) for a Recombinant OspA Lyme Disease Vaccine

Autor: Van Hoecke, C., Beran, J.

Publikováno v: Clinical Infectious Diseases, 1999 Jun 01. 28(6), 1260-1264.

Externí odkaz: https://www.jstor.org/stable/4481864

A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120 W61D derived from dual tropic R5X4 HIV-1 ACH320

Autor: McCormack, S. ^*, Tilzey, A., Carmichael, A., Gotch, F., Kepple, J., Newberry, A., Jones, G., Lister, S., Beddows, S., Cheingsong, R., Rees, A., Babiker, A., Banatvala, J., Bruck, C., Darbyshire, J., Tyrrell, D., Van Hoecke, C., Weber, J.

Publikováno v: In Vaccine 2000 18(13):1166-1177

Longterm survey (7 years) in a population at risk for Lyme borreliosis: what happens to the seropositive individuals?

Autor: Fahrer, H, Sauvain, M J, Zhioua, E, Van Hoecke, C, Gern, L E

Publikováno v: Fahrer, H; Sauvain, M J; Zhioua, E; Van Hoecke, C; Gern, L E (1998). Longterm survey (7 years) in a population at risk for Lyme borreliosis: what happens to the seropositive individuals? European journal of epidemiology, 14(2), pp. 117-23. Dordrecht: Springer 10.1023/A:1007404620701

In 1986, a 26% seroprevalence of IgG- anti-Borrelia burgdorferi antibodies was observed among 950 orienteers and the incidence of new clinical infections was 0.8%. In 1993, a total of 305 seropositive orienteers were reexamined. During that time, 15

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c7b1109db34b206c62d22de99f2760

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.